Guardant Health Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

GH$155.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

Condensed Consolidated Statements of Stockholders’ (Deficit) Equity (unaudited)

(in thousands, except share data)

	Three Months Ended September 30, 2024
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit
Shares · Amount
Balance as of July 1, 2024	122,969,580	$1	$2,363,501	$(5,640)	$(2,359,475)	$(1,613)
Issuance of common stock upon exercise of stock options	4,143	—	20	—	—	20
Vesting of restricted stock units	184,695	—	—	—	—	—
Taxes paid related to net share settlement of restricted stock units	—	—	(2,874)	—	—	(2,874)
Stock-based compensation	—	—	49,769	—	—	49,769
Other comprehensive income	—	—	—	2,356	—	2,356
Net loss	—	—	—	—	(107,754)	(107,754)
Balance as of September 30, 2024	123,158,418	$1	$2,410,416	$(3,284)	$(2,467,229)	$(60,096)

	Three Months Ended September 30, 2023
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance as of July 1, 2023	117,662,134	$1	$2,169,911	$(8,469)	$(1,868,717)	$292,726
Issuance of common stock upon exercise of stock options	8,989	—	70	—	—	70
Vesting of restricted stock units	178,032	—	—	—	—	—
Taxes paid related to net share settlement of restricted stock units	—	—	(3,003)	—	—	(3,003)
Stock-based compensation	—	—	21,819	—	—	21,819
Other comprehensive income	—	—	—	2,789	—	2,789
Net loss	—	—	—	—	(86,102)	(86,102)
Balance as of September 30, 2023	117,849,155	$1	$2,188,797	$(5,680)	$(1,954,819)	$228,299

	Nine Months Ended September 30, 2024
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Equity (Deficit)
Shares · Amount
Balance as of January 1, 2024	121,629,861	$1	$2,304,220	$(3,675)	$(2,141,862)	$158,684
Issuance of common stock upon exercise of stock options	581,495	—	2,597	—	—	2,597
Vesting of restricted stock units	575,236	—	—	—	—	—
Common stock issued under employee stock purchase plan	371,826	—	7,212	—	—	7,212
Taxes paid related to net share settlement of restricted stock units	—	—	(7,658)	—	—	(7,658)
Stock-based compensation	—	—	104,045	—	—	104,045
Other comprehensive income	—	—	—	391	—	391
Net loss	—	—	—	—	(325,367)	(325,367)
Balance as of September 30, 2024	123,158,418	$1	$2,410,416	$(3,284)	$(2,467,229)	$(60,096)

	Nine Months Ended September 30, 2023
Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance as of January 1, 2023	102,619,383	$1	$1,742,114	$(19,522)	$(1,662,413)	$60,180
Issuance of common stock in public offering, net of offering costs of $21,131	14,375,000	—	381,369	—	—	381,369
Issuance of common stock upon exercise of stock options	40,868	—	290	—	—	290
Vesting of restricted stock units	515,123	—	—	—	—	—
Common stock issued under employee stock purchase plan	298,781	—	6,697	—	—	6,697
Taxes paid related to net share settlement of restricted stock units	—	—	(8,112)	—	—	(8,112)
Stock-based compensation	—	—	66,439	—	—	66,439
Other comprehensive income	—	—	—	13,842	—	13,842
Net loss	—	—	—	—	(292,406)	(292,406)
Balance as of September 30, 2023	117,849,155	$1	$2,188,797	$(5,680)	$(1,954,819)	$228,299

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.